Children with psoriasis and COVID-19: factors associated with an unfavourable COVID-19 course, and the impact of infection on disease progression (Chi-PsoCov registry)

the Groupe de Recherche sur le Psoriasis (GrPso) of the Société Française de Dermatologie, the Groupe de recherche de la Société Française de Dermatologie Pédiatrique (GR SFDP), the PsoProtect study group, the British Society of Paediatric Dermatology (BPSD), and the Società Italiana di Dermatologia Pediatrica (S.I.Der.P.)

doi:10.1111/jdv.18361

Children with psoriasis and COVID-19: factors associated with an unfavourable COVID-19 course, and the impact of infection on disease progression (Chi-PsoCov registry)

the Groupe de Recherche sur le Psoriasis (GrPso) of the Société Française de Dermatologie, the Groupe de recherche de la Société Française de Dermatologie Pédiatrique (GR SFDP), the PsoProtect study group, the British Society of Paediatric Dermatology (BPSD), and the Società Italiana di Dermatologia Pediatrica (S.I.Der.P.)

Dermatology

Research output: Contribution to journal › Article › peer-review

10 Citations (Scopus)

Abstract

Background: The COVID-19 pandemic has raised questions regarding the management of chronic skin diseases, especially in patients on systemic treatments. Data concerning the use of biologics in adults with psoriasis are reassuring, but data specific to children are missing. Moreover, COVID-19 could impact the course of psoriasis in children. Objectives: The aim of this study was therefore to assess the impact of COVID-19 on the psoriasis of children, and the severity of the infection in relation to systemic treatments. Methods: We set up an international registry of paediatric psoriasis patients. Children were included if they were under 18 years of age, had a history of psoriasis, or developed it within 1 month of COVID-19 and had COVID-19 with or without symptoms. Results: One hundred and twenty episodes of COVID-19 in 117 children (mean age: 12.4 years) were reported. The main clinical form of psoriasis was plaque type (69.4%). Most children were without systemic treatment (54.2%); 33 (28.3%) were on biologic therapies, and 24 (20%) on non-biologic systemic drugs. COVID-19 was confirmed in 106 children (88.3%) and 3 children had two COVID-19 infections each. COVID-19 was symptomatic for 75 children (62.5%) with a mean duration of 6.5 days, significantly longer for children on non-biologic systemic treatments (P = 0.02) and without systemic treatment (P = 0.006) when compared with children on biologics. The six children who required hospitalization were more frequently under non-biologic systemic treatment when compared with the other children (P = 0.01), and particularly under methotrexate (P = 0.03). After COVID-19, the psoriasis worsened in 17 cases (15.2%). Nine children (8%) developed a psoriasis in the month following COVID-19, mainly a guttate form (P = 0.01). Discussion: Biologics appear to be safe with no increased risk of severe form of COVID-19 in children with psoriasis. COVID-19 was responsible for the development of psoriasis or the worsening of a known psoriasis for some children.

Original language	English
Pages (from-to)	2076-2086
Number of pages	11
Journal	Journal of the European Academy of Dermatology and Venereology
Volume	36
Issue number	11
DOIs	https://doi.org/10.1111/jdv.18361
Publication status	Published - Nov 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/jdv.18361

Cite this

the Groupe de Recherche sur le Psoriasis (GrPso) of the Société Française de Dermatologie, the Groupe de recherche de la Société Française de Dermatologie Pédiatrique (GR SFDP), the PsoProtect study group, the British Society of Paediatric Dermatology (BPSD), and the Società Italiana di Dermatologia Pediatrica (S.I.Der.P.) (2022). Children with psoriasis and COVID-19: factors associated with an unfavourable COVID-19 course, and the impact of infection on disease progression (Chi-PsoCov registry). Journal of the European Academy of Dermatology and Venereology, 36(11), 2076-2086. https://doi.org/10.1111/jdv.18361

the Groupe de Recherche sur le Psoriasis (GrPso) of the Société Française de Dermatologie, the Groupe de recherche de la Société Française de Dermatologie Pédiatrique (GR SFDP), the PsoProtect study group, the British Society of Paediatric Dermatology (BPSD), and the Società Italiana di Dermatologia Pediatrica (S.I.Der.P.). / Children with psoriasis and COVID-19 : factors associated with an unfavourable COVID-19 course, and the impact of infection on disease progression (Chi-PsoCov registry). In: Journal of the European Academy of Dermatology and Venereology. 2022 ; Vol. 36, No. 11. pp. 2076-2086.

@article{4f084d424344433ba08d25bb7da0101b,

title = "Children with psoriasis and COVID-19: factors associated with an unfavourable COVID-19 course, and the impact of infection on disease progression (Chi-PsoCov registry)",

abstract = "Background: The COVID-19 pandemic has raised questions regarding the management of chronic skin diseases, especially in patients on systemic treatments. Data concerning the use of biologics in adults with psoriasis are reassuring, but data specific to children are missing. Moreover, COVID-19 could impact the course of psoriasis in children. Objectives: The aim of this study was therefore to assess the impact of COVID-19 on the psoriasis of children, and the severity of the infection in relation to systemic treatments. Methods: We set up an international registry of paediatric psoriasis patients. Children were included if they were under 18 years of age, had a history of psoriasis, or developed it within 1 month of COVID-19 and had COVID-19 with or without symptoms. Results: One hundred and twenty episodes of COVID-19 in 117 children (mean age: 12.4 years) were reported. The main clinical form of psoriasis was plaque type (69.4%). Most children were without systemic treatment (54.2%); 33 (28.3%) were on biologic therapies, and 24 (20%) on non-biologic systemic drugs. COVID-19 was confirmed in 106 children (88.3%) and 3 children had two COVID-19 infections each. COVID-19 was symptomatic for 75 children (62.5%) with a mean duration of 6.5 days, significantly longer for children on non-biologic systemic treatments (P = 0.02) and without systemic treatment (P = 0.006) when compared with children on biologics. The six children who required hospitalization were more frequently under non-biologic systemic treatment when compared with the other children (P = 0.01), and particularly under methotrexate (P = 0.03). After COVID-19, the psoriasis worsened in 17 cases (15.2%). Nine children (8%) developed a psoriasis in the month following COVID-19, mainly a guttate form (P = 0.01). Discussion: Biologics appear to be safe with no increased risk of severe form of COVID-19 in children with psoriasis. COVID-19 was responsible for the development of psoriasis or the worsening of a known psoriasis for some children.",

author = "{the Groupe de Recherche sur le Psoriasis (GrPso) of the Soci{\'e}t{\'e} Fran{\c c}aise de Dermatologie, the Groupe de recherche de la Soci{\'e}t{\'e} Fran{\c c}aise de Dermatologie P{\'e}diatrique (GR SFDP), the PsoProtect study group, the British Society of Paediatric Dermatology (BPSD), and the Societ{\`a} Italiana di Dermatologia Pediatrica (S.I.Der.P.)} and J. Zitouni and Bursztejn, {A. C.} and {Belloni Fortina}, A. and A. Beauchet and {Di Lernia}, V. and A. Lesiak and J. Thomas and Z. Topkarci and N. Murashkin and P. Brzezinski and T. Torres and A. Chiriac and C. Luca and T. McPherson and M. Akinde and A. Maruani and R. Epishev and {Vidaurri de la Cruz}, H. and Luna, {P. C.} and {Amy de la Bret{\^e}que}, M. and A. Lasek and E. Bourrat and M. Bachelerie and S. Mallet and M. Steff and A. Bellissen and I. Neri and E. Zafiriou and {van den Reek}, {J. M.P.A.} and E. Sonkoly and Mahil, {S. K.} and Smith, {C. H.} and C. Flohr and H. Bachelez and E. Mah{\'e}",

note = "Funding Information: V. Di Lernia has undertaken activities as a paid consultant, advisor or speaker for AbbVie, Janssen Cilag, Novartis and Sanofi. A. Lesiak has undertaken activities as a paid consultant, advisor or speaker for AbbVie, Almirall, Janssen Cilag, Leo Pharma, Lilly, Novartis, Pfizer, Sandoz and Pierre‐Fabre. N. Murashkin has undertaken activities as a paid consultant, advisor or speaker for Jansen Cilag, Eli Lilly, Novartis, AbbVie, Amryt Pharma, Pfizer, Celgene, M{\"o}lnlycke Health Care AB, Zeldis Pharma, Galderma and Bayer. T. Torres has undertaken activities as a paid consultant, advisor or speaker for AbbVie, Almirall, Amgen, Arena Pharmaceuticals, Biocad, Boehringer Ingelheim, Bristol‐Myers Squibb, Celgene, Eli Lilly, Janssen, Leo Pharma, MSD, Novartis, Pfizer, Samsung‐Bioepis, Sandoz and Sanofi. T. McPherson has undertaken paid speaker fees for AbbVie, Leo pharma and Sanofi. R. Epishev has undertaken activities as a paid consultant, advisor or speaker for Eli Lilly, Novartis, AbbVie, Amryt Pharma, Janssen, Pfizer, Celgene and M{\"o}lnlycke Health Care AB. I. Neri has undertaken activities as a paid consultant, advisor or speaker for Janssen Cilag, Sanofi and Lilly. J M.P.A. van den Reek carried out clinical trials for AbbVie, Celgene and Janssen and has received speaking fees/attended advisory boards from AbbVie, Janssen, BMS, Almirall, Leo Pharma, Novartis, UCB and Eli Lilly and reimbursement for attending a symposium from Janssen, Pfizer, Celgene and AbbVie. All funding is not personal but goes to the independent research fund of the department of dermatology of Radboudumc Nijmegen, the Netherlands. E. Sonkoly has undertaken activities as a paid consultant, advisor or speaker for Eli Lilly, AbbVie, Janssen Cilag, Leo Pharma, Bristol Myers Squibb, Novartis and UCB. S.K. Mahil has received departmental funding from AbbVie, Celgene, Eli Lilly, Janssen‐Cilag, Novartis, Sanofi and UCB. C. Smith has received departmental research funding from AbbVie, Novartis, Pfizer and Sanofi and has served as an investigator on Medical Research Council – and Horizon 2020 – funded consortia with industry partners (see psort.org.uk and biomap – imi.eu). C. Flohr is Chief Investigator of the UK National Institute for Health Research‐funded TREAT (ISRCTN15837754) and SOFTER ( Clinicaltrials.gov : NCT03270566) trials as well as the UK‐Irish Atopic eczema Systemic Therapy Register (A‐STAR; ISRCTN11210918) and a Principle Investigator in the European Union (EU) Horizon 2020‐funded BIOMAP Consortium ( http://www.biomap‐imi.eu/ ). He also leads the EU Trans‐Foods consortium. His department has received funding from Sanofi‐Genzyme for skin microbiome work. H. Bachelez has undertaken activities as a paid consultant, advisor or speaker for AbbVie, Almirall, Anaptysbio, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Kyowa Kirin, Janssen Cilag, Leo Pharma, Lilly, Novartis, UCB and received research funding support from Boehringer Ingelheim, Bristol Myers Squibb, Leo Pharma, Novartis and Pfizer. E. Mah{\'e} has undertaken activities as a paid consultant, advisor or speaker for AbbVie, Amgen, Celgene, Janssen Cilag, Leo Pharma, Lilly, Novartis and Sanofi. Other authors have no conflicts of interest to disclose. Publisher Copyright: {\textcopyright} 2022 European Academy of Dermatology and Venereology.",

year = "2022",

month = nov,

doi = "10.1111/jdv.18361",

language = "English",

volume = "36",

pages = "2076--2086",

journal = "Journal of the European Academy of Dermatology and Venereology",

issn = "0926-9959",

publisher = "Wiley",

number = "11",

}

the Groupe de Recherche sur le Psoriasis (GrPso) of the Société Française de Dermatologie, the Groupe de recherche de la Société Française de Dermatologie Pédiatrique (GR SFDP), the PsoProtect study group, the British Society of Paediatric Dermatology (BPSD), and the Società Italiana di Dermatologia Pediatrica (S.I.Der.P.) 2022, 'Children with psoriasis and COVID-19: factors associated with an unfavourable COVID-19 course, and the impact of infection on disease progression (Chi-PsoCov registry)', Journal of the European Academy of Dermatology and Venereology, vol. 36, no. 11, pp. 2076-2086. https://doi.org/10.1111/jdv.18361

Children with psoriasis and COVID-19: factors associated with an unfavourable COVID-19 course, and the impact of infection on disease progression (Chi-PsoCov registry). / the Groupe de Recherche sur le Psoriasis (GrPso) of the Société Française de Dermatologie, the Groupe de recherche de la Société Française de Dermatologie Pédiatrique (GR SFDP), the PsoProtect study group, the British Society of Paediatric Dermatology (BPSD), and the Società Italiana di Dermatologia Pediatrica (S.I.Der.P.).
In: Journal of the European Academy of Dermatology and Venereology, Vol. 36, No. 11, 11.2022, p. 2076-2086.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Children with psoriasis and COVID-19

T2 - factors associated with an unfavourable COVID-19 course, and the impact of infection on disease progression (Chi-PsoCov registry)

AU - the Groupe de Recherche sur le Psoriasis (GrPso) of the Société Française de Dermatologie, the Groupe de recherche de la Société Française de Dermatologie Pédiatrique (GR SFDP), the PsoProtect study group, the British Society of Paediatric Dermatology (BP

AU - Zitouni, J.

AU - Bursztejn, A. C.

AU - Belloni Fortina, A.

AU - Beauchet, A.

AU - Di Lernia, V.

AU - Lesiak, A.

AU - Thomas, J.

AU - Topkarci, Z.

AU - Murashkin, N.

AU - Brzezinski, P.

AU - Torres, T.

AU - Chiriac, A.

AU - Luca, C.

AU - McPherson, T.

AU - Akinde, M.

AU - Maruani, A.

AU - Epishev, R.

AU - Vidaurri de la Cruz, H.

AU - Luna, P. C.

AU - Amy de la Bretêque, M.

AU - Lasek, A.

AU - Bourrat, E.

AU - Bachelerie, M.

AU - Mallet, S.

AU - Steff, M.

AU - Bellissen, A.

AU - Neri, I.

AU - Zafiriou, E.

AU - van den Reek, J. M.P.A.

AU - Sonkoly, E.

AU - Mahil, S. K.

AU - Smith, C. H.

AU - Flohr, C.

AU - Bachelez, H.

AU - Mahé, E.

N1 - Funding Information: V. Di Lernia has undertaken activities as a paid consultant, advisor or speaker for AbbVie, Janssen Cilag, Novartis and Sanofi. A. Lesiak has undertaken activities as a paid consultant, advisor or speaker for AbbVie, Almirall, Janssen Cilag, Leo Pharma, Lilly, Novartis, Pfizer, Sandoz and Pierre‐Fabre. N. Murashkin has undertaken activities as a paid consultant, advisor or speaker for Jansen Cilag, Eli Lilly, Novartis, AbbVie, Amryt Pharma, Pfizer, Celgene, Mölnlycke Health Care AB, Zeldis Pharma, Galderma and Bayer. T. Torres has undertaken activities as a paid consultant, advisor or speaker for AbbVie, Almirall, Amgen, Arena Pharmaceuticals, Biocad, Boehringer Ingelheim, Bristol‐Myers Squibb, Celgene, Eli Lilly, Janssen, Leo Pharma, MSD, Novartis, Pfizer, Samsung‐Bioepis, Sandoz and Sanofi. T. McPherson has undertaken paid speaker fees for AbbVie, Leo pharma and Sanofi. R. Epishev has undertaken activities as a paid consultant, advisor or speaker for Eli Lilly, Novartis, AbbVie, Amryt Pharma, Janssen, Pfizer, Celgene and Mölnlycke Health Care AB. I. Neri has undertaken activities as a paid consultant, advisor or speaker for Janssen Cilag, Sanofi and Lilly. J M.P.A. van den Reek carried out clinical trials for AbbVie, Celgene and Janssen and has received speaking fees/attended advisory boards from AbbVie, Janssen, BMS, Almirall, Leo Pharma, Novartis, UCB and Eli Lilly and reimbursement for attending a symposium from Janssen, Pfizer, Celgene and AbbVie. All funding is not personal but goes to the independent research fund of the department of dermatology of Radboudumc Nijmegen, the Netherlands. E. Sonkoly has undertaken activities as a paid consultant, advisor or speaker for Eli Lilly, AbbVie, Janssen Cilag, Leo Pharma, Bristol Myers Squibb, Novartis and UCB. S.K. Mahil has received departmental funding from AbbVie, Celgene, Eli Lilly, Janssen‐Cilag, Novartis, Sanofi and UCB. C. Smith has received departmental research funding from AbbVie, Novartis, Pfizer and Sanofi and has served as an investigator on Medical Research Council – and Horizon 2020 – funded consortia with industry partners (see psort.org.uk and biomap – imi.eu). C. Flohr is Chief Investigator of the UK National Institute for Health Research‐funded TREAT (ISRCTN15837754) and SOFTER ( Clinicaltrials.gov : NCT03270566) trials as well as the UK‐Irish Atopic eczema Systemic Therapy Register (A‐STAR; ISRCTN11210918) and a Principle Investigator in the European Union (EU) Horizon 2020‐funded BIOMAP Consortium ( http://www.biomap‐imi.eu/ ). He also leads the EU Trans‐Foods consortium. His department has received funding from Sanofi‐Genzyme for skin microbiome work. H. Bachelez has undertaken activities as a paid consultant, advisor or speaker for AbbVie, Almirall, Anaptysbio, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Kyowa Kirin, Janssen Cilag, Leo Pharma, Lilly, Novartis, UCB and received research funding support from Boehringer Ingelheim, Bristol Myers Squibb, Leo Pharma, Novartis and Pfizer. E. Mahé has undertaken activities as a paid consultant, advisor or speaker for AbbVie, Amgen, Celgene, Janssen Cilag, Leo Pharma, Lilly, Novartis and Sanofi. Other authors have no conflicts of interest to disclose. Publisher Copyright: © 2022 European Academy of Dermatology and Venereology.

PY - 2022/11

Y1 - 2022/11

N2 - Background: The COVID-19 pandemic has raised questions regarding the management of chronic skin diseases, especially in patients on systemic treatments. Data concerning the use of biologics in adults with psoriasis are reassuring, but data specific to children are missing. Moreover, COVID-19 could impact the course of psoriasis in children. Objectives: The aim of this study was therefore to assess the impact of COVID-19 on the psoriasis of children, and the severity of the infection in relation to systemic treatments. Methods: We set up an international registry of paediatric psoriasis patients. Children were included if they were under 18 years of age, had a history of psoriasis, or developed it within 1 month of COVID-19 and had COVID-19 with or without symptoms. Results: One hundred and twenty episodes of COVID-19 in 117 children (mean age: 12.4 years) were reported. The main clinical form of psoriasis was plaque type (69.4%). Most children were without systemic treatment (54.2%); 33 (28.3%) were on biologic therapies, and 24 (20%) on non-biologic systemic drugs. COVID-19 was confirmed in 106 children (88.3%) and 3 children had two COVID-19 infections each. COVID-19 was symptomatic for 75 children (62.5%) with a mean duration of 6.5 days, significantly longer for children on non-biologic systemic treatments (P = 0.02) and without systemic treatment (P = 0.006) when compared with children on biologics. The six children who required hospitalization were more frequently under non-biologic systemic treatment when compared with the other children (P = 0.01), and particularly under methotrexate (P = 0.03). After COVID-19, the psoriasis worsened in 17 cases (15.2%). Nine children (8%) developed a psoriasis in the month following COVID-19, mainly a guttate form (P = 0.01). Discussion: Biologics appear to be safe with no increased risk of severe form of COVID-19 in children with psoriasis. COVID-19 was responsible for the development of psoriasis or the worsening of a known psoriasis for some children.

AB - Background: The COVID-19 pandemic has raised questions regarding the management of chronic skin diseases, especially in patients on systemic treatments. Data concerning the use of biologics in adults with psoriasis are reassuring, but data specific to children are missing. Moreover, COVID-19 could impact the course of psoriasis in children. Objectives: The aim of this study was therefore to assess the impact of COVID-19 on the psoriasis of children, and the severity of the infection in relation to systemic treatments. Methods: We set up an international registry of paediatric psoriasis patients. Children were included if they were under 18 years of age, had a history of psoriasis, or developed it within 1 month of COVID-19 and had COVID-19 with or without symptoms. Results: One hundred and twenty episodes of COVID-19 in 117 children (mean age: 12.4 years) were reported. The main clinical form of psoriasis was plaque type (69.4%). Most children were without systemic treatment (54.2%); 33 (28.3%) were on biologic therapies, and 24 (20%) on non-biologic systemic drugs. COVID-19 was confirmed in 106 children (88.3%) and 3 children had two COVID-19 infections each. COVID-19 was symptomatic for 75 children (62.5%) with a mean duration of 6.5 days, significantly longer for children on non-biologic systemic treatments (P = 0.02) and without systemic treatment (P = 0.006) when compared with children on biologics. The six children who required hospitalization were more frequently under non-biologic systemic treatment when compared with the other children (P = 0.01), and particularly under methotrexate (P = 0.03). After COVID-19, the psoriasis worsened in 17 cases (15.2%). Nine children (8%) developed a psoriasis in the month following COVID-19, mainly a guttate form (P = 0.01). Discussion: Biologics appear to be safe with no increased risk of severe form of COVID-19 in children with psoriasis. COVID-19 was responsible for the development of psoriasis or the worsening of a known psoriasis for some children.

UR - http://www.scopus.com/inward/record.url?scp=85133816043&partnerID=8YFLogxK

U2 - 10.1111/jdv.18361

DO - 10.1111/jdv.18361

M3 - Article

C2 - 35748102

AN - SCOPUS:85133816043

SN - 0926-9959

VL - 36

SP - 2076

EP - 2086

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

IS - 11

ER -

the Groupe de Recherche sur le Psoriasis (GrPso) of the Société Française de Dermatologie, the Groupe de recherche de la Société Française de Dermatologie Pédiatrique (GR SFDP), the PsoProtect study group, the British Society of Paediatric Dermatology (BPSD), and the Società Italiana di Dermatologia Pediatrica (S.I.Der.P.). Children with psoriasis and COVID-19: factors associated with an unfavourable COVID-19 course, and the impact of infection on disease progression (Chi-PsoCov registry). Journal of the European Academy of Dermatology and Venereology. 2022 Nov;36(11):2076-2086. doi: 10.1111/jdv.18361

Children with psoriasis and COVID-19: factors associated with an unfavourable COVID-19 course, and the impact of infection on disease progression (Chi-PsoCov registry)

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this